JP5755731B2 - Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド - Google Patents

Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド Download PDF

Info

Publication number
JP5755731B2
JP5755731B2 JP2013513340A JP2013513340A JP5755731B2 JP 5755731 B2 JP5755731 B2 JP 5755731B2 JP 2013513340 A JP2013513340 A JP 2013513340A JP 2013513340 A JP2013513340 A JP 2013513340A JP 5755731 B2 JP5755731 B2 JP 5755731B2
Authority
JP
Japan
Prior art keywords
alkyl
group
cyclopenta
pentamethyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013513340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527243A5 (enExample
JP2013527243A (ja
Inventor
アリシア・レゲイロ−レン
チェン・リウ
ジェイコブ・スウィドースキ
ニコラス・エイ・ミーンウェル
シン−ユエン・シット
チェン・ジエ
ヤン・チェン
ナイ・シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013527243A publication Critical patent/JP2013527243A/ja
Publication of JP2013527243A5 publication Critical patent/JP2013527243A5/ja
Application granted granted Critical
Publication of JP5755731B2 publication Critical patent/JP5755731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013513340A 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド Expired - Fee Related JP5755731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35133210P 2010-06-04 2010-06-04
US61/351,332 2010-06-04
PCT/US2011/038884 WO2011153319A1 (en) 2010-06-04 2011-06-02 C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (3)

Publication Number Publication Date
JP2013527243A JP2013527243A (ja) 2013-06-27
JP2013527243A5 JP2013527243A5 (enExample) 2014-07-17
JP5755731B2 true JP5755731B2 (ja) 2015-07-29

Family

ID=44627254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513340A Expired - Fee Related JP5755731B2 (ja) 2010-06-04 2011-06-02 Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド

Country Status (20)

Country Link
US (1) US8802661B2 (enExample)
EP (1) EP2576586B1 (enExample)
JP (1) JP5755731B2 (enExample)
CN (1) CN102985438B (enExample)
AR (1) AR081638A1 (enExample)
BR (1) BR112012030810A2 (enExample)
CA (1) CA2801491C (enExample)
DK (1) DK2576586T3 (enExample)
EA (1) EA026140B1 (enExample)
ES (1) ES2548905T3 (enExample)
HR (1) HRP20150977T1 (enExample)
HU (1) HUE026662T2 (enExample)
MX (1) MX2012013628A (enExample)
PL (1) PL2576586T3 (enExample)
PT (1) PT2576586E (enExample)
RS (1) RS54239B1 (enExample)
SI (1) SI2576586T1 (enExample)
SM (1) SMT201500272B (enExample)
TW (1) TW201201792A (enExample)
WO (1) WO2011153319A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2670764T1 (sl) * 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
US20140221361A1 (en) * 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) * 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
WO2015198263A2 (en) * 2014-06-26 2015-12-30 Hetero Research Foundation Novel betulinic proline substituted derivatives as hiv inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 C17-아릴 치환된 베툴린산 유사체
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
ES2281960T3 (es) * 1998-03-02 2007-10-01 The University Of North Carolina At Chapel Hill Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso.
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
NZ538896A (en) * 2002-09-26 2007-10-26 Niigata University Of Pharmacy Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
US7282521B2 (en) 2004-05-24 2007-10-16 University Of North Carolina At Chapel Hill Anti-retroviral moronic acid derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1986654A2 (en) * 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
WO2008097341A2 (en) 2006-07-26 2008-08-14 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) * 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
WO2009129548A1 (en) * 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US20120302534A1 (en) * 2010-02-11 2012-11-29 Daxin Gao Derivatives of betulin

Also Published As

Publication number Publication date
EP2576586B1 (en) 2015-08-12
HRP20150977T1 (hr) 2015-10-09
EA201270800A1 (ru) 2013-04-30
BR112012030810A2 (pt) 2019-09-24
EA026140B1 (ru) 2017-03-31
JP2013527243A (ja) 2013-06-27
RS54239B1 (sr) 2015-12-31
EP2576586A1 (en) 2013-04-10
SI2576586T1 (sl) 2015-11-30
US20120142653A1 (en) 2012-06-07
TW201201792A (en) 2012-01-16
MX2012013628A (es) 2012-12-17
CA2801491A1 (en) 2011-12-08
CA2801491C (en) 2018-01-23
HUE026662T2 (en) 2016-06-28
PT2576586E (pt) 2015-10-23
ES2548905T3 (es) 2015-10-21
WO2011153319A1 (en) 2011-12-08
AR081638A1 (es) 2012-10-10
PL2576586T3 (pl) 2016-01-29
SMT201500272B (it) 2016-01-08
DK2576586T3 (en) 2015-11-23
CN102985438B (zh) 2016-05-18
CN102985438A (zh) 2013-03-20
US8802661B2 (en) 2014-08-12

Similar Documents

Publication Publication Date Title
JP5755731B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド
JP6000283B2 (ja) Hiv成熟阻害剤としてのc−3修飾ベツリン酸誘導体のc−28アミン
JP5752789B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体
JP6155285B2 (ja) Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド
JP6212545B2 (ja) Hiv成熟阻害活性を有するc−17二環式アミンのトリテルペノイド
JP6001560B2 (ja) Hiv成熟阻害活性を有するc−17およびc−3修飾トリテルペノイド
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
AU2014215468B2 (en) C-19 modified triterpenoids with HIV maturation inhibitory activity
KR102411082B1 (ko) 할로알킬 치환기를 지니는 비­방향족 고리에 의해 위치 3에서 치환된,hiv 성숙화 억제 활성을 갖는 트리테르페노이드
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
JP2017533934A (ja) C17アリール置換ベツリン酸類似体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150527

R150 Certificate of patent or registration of utility model

Ref document number: 5755731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees